Agoracom Blog Home

Posts Tagged ‘weed’

Bougainville Ventures Inc. $BOG.ca Provides Corporate Update & Signs LOI with Oregon Hemp CBD Producer $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 2:06 PM on Monday, October 29th, 2018

681747 5720 copy 2

  • Signed a letter of intent to enter into a financing and profit-sharing agreement with Worm Castings Farms Inc., the sole owner of an Oregon state hemp production and processing license issued by the Oregon State Regulatory approval board

Bougainville Ventures Inc. has signed a letter of intent to enter into a financing and profit-sharing agreement with Worm Castings Farms Inc., the sole owner of an Oregon state hemp production and processing licence issued by the Oregon State Regulatory approval board. The material terms of the LOI are summarized below. LOI Terms

1. The parties shall enter into a funding and profit sharing agreement with both companies receiving dividends. The profit sharing percentages will be stipulated in the definitive agreement.

2. Bougainville will agree to issue to Worm Castings 600,000 shares of Bougainville Ventures Inc. for assets and goodwill of Worm Castings.

3. Bougainville will also agree to raise $350,000 USD to be used to fund Worm Castings’ business plan. The funds are expected to be provided on the following schedule:

a. $75,000 by November 7, 2018

b. $75,000 by November 30, 2018

c. $200,000 by December 31, 2018

4. Worm Castings will submit to Bougainville a complete list of assets to be included in the definitive agreement

About Worm Castings Farms Inc.

Worm Castings is a natural hemp company that currently has 10 acres of industrial hemp ready for harvest. They plant premium high quality cloned feminized hemp plants with 10-15% CBD and 0.3% THC resulting in maximized CBD oil content within each plant. In addition, they provide proven topsoil mix that improves plant growth by 20%. With this soil quality, they can expect to set standards in respective markets within the hemp industry.

CEO, Andy Jagpal Comments: “The objective of this project is to extract CBD oil from Hemp stock by providing the initial capital for the continued development of the 10 acre farmland and is a step in the right direction in diversifying our portfolio of companies in the cannabis infrastructure space .”

Oroville Campus Tier -3 Tenant Update

The Company also reports that it has recently become aware that Marijuana Company of America, Inc. (“MCOA”) has purportedly terminated its joint venture agreement with the Company dated March 16, 2017 (“JV Agreement”), and that it may have commenced legal action against the Company relating to various claims. The Company has not been served with a claim and has not receive a notice of default related to the JV agreement and will investigate this matter further. If subject to a claim, the Company intends to defend vigorously and to pursue all legal actions available to it. The Company notes that the JV Agreement relating to the acre of the 4.33 acre parcel of land located at Oroville Campus will continue for occupancy for its tenant.

Oroville Campus Tier -2 Tenant Update

The Company notes that the new I-502 Tier-2 licensee tenant and lease agreement relating to the 3.33 acre parcel of land in the Oroville Campus announced in the Company’s news release dated October 23, 2018 is not subject to the JV Agreement with MCOA and indeed resides on a separate parcel of land. Operations relating to such tenant are proceeding as previously announced.

About Bougainville Ventures, Inc.

Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost. Bougainville has 30,000 sqft in near production in Oroville, WA.

We seek Safe Harbor.

#Marijuana shortages abound in Canada in just second week of legalization $BOG.ca NBUD.ca $MCOA $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 10:54 AM on Monday, October 29th, 2018

  • The Canadian cannabis industry is still reeling from sky-high demand in the second week of legalization, with growers expressing frustration at the length of time it’s taking to get licensed as shelves sit empty.
  • “We’re biting our nails and I think our shareholders are biting their nails too,” said Anthony Durkacz, director at FSD Pharma Inc., an Ontario-based producer that received its cultivation licence a year ago and is still waiting for its sales licence. “We want to be supplying.”

People check out the sample counter at a cannabis store in Winnipeg, Man., on Oct. 17.Canadian Press/John Woods

Kristine Owram

The Canadian cannabis industry is still reeling from sky-high demand in the second week of legalization, with growers expressing frustration at the length of time it’s taking to get licensed as shelves sit empty.

“We’re biting our nails and I think our shareholders are biting their nails too,” said Anthony Durkacz, director at FSD Pharma Inc., an Ontario-based producer that received its cultivation licence a year ago and is still waiting for its sales licence. “We want to be supplying.”

Every province, not just Manitoba, is receiving less cannabis than originally requested

The process of getting a sales licence from Health Canada is onerous, according to Durkacz. After receiving a cultivation license, a grower must produce two full crops, send them off for testing, get its sales software audited, and then submit a completed application for the sales licence, which can take up to 341 days to process, he said.

“So even after you’ve done everything and done everything right you could be waiting up to a year to get the licence,” he said.

Customers lineup at a government cannabis store Oct. 19, in Montreal on the third day of the legal cannabis sales in Canada. Canadian Press/Ryan RemiorzCanada became the first major economy to legalize recreational cannabis on Oct. 17, taking the lead in a global market that’s expected to reach US$32 billion in consumer spending by 2022, according to Arcview Market Research and BDS Analytics. The euphoria that sent pot stocks soaring in the lead-up to legalization has faded, with the BI Canada Cannabis Competitive Peers index losing 26 per cent over seven sessions before rebounding on Thursday.

While some growers wait for their licences, others are struggling to keep up with demand. The government-run Ontario Cannabis Store received 100,000 orders in its first 24 hours. In Quebec, online and in-store orders totalled nearly 140,000 in the first week of legalization, and the provincial-owned retailer indicated Wednesday it may have to close some locations as producers couldn’t meet demand. Producers will have a “colossal” amount of work to do to ensure supply, the Societe Quebecoise du Cannabis said in a statement.

A man holds a bag of marijuana he bought in a cannabis store in Quebec City, on Oct. 17. Alice Chiche/AFP/Getty ImagesThe problem is that no one knew what the demand curve would look like after a century of prohibition, said Bruce Linton, chief executive officer of Canopy Growth Corp., which has secured more than a third of total Canadian supply committed to date.

Canopy shipped approximately 1 million orders of medical cannabis in its first four years of operations. It expects to ship more than 1 million units of recreational pot in the first four weeks after legalization, Linton said.

‘Just Outstanding’

“The response has been pretty unbelievable,” Linton said. “I don’t think everything will run out but you might not be able to get the identical stuff you got last time.”

He added that Canopy is sending out orders as fast as it can pack and ship them, but there have been delays in getting new product up on the provincial websites. It will start shipping out new products, including Tweed-brand gel caps and pre-rolled joints, over the next week and a half.

Bruce Linton (left), Canopy Growth CEO, in St. Johns, Newfoundland sells the first gram of legal pot at the Tweed store at the stroke of midnight Oct. 17. Julie Oliver/PostmediaInitial demand at Alberta Gaming, Liquor and Cannabis was “just outstanding,” said Chara Goodings, a spokeswoman for the government regulator that’s overseeing sales in the western province. “But it has created some struggles with our supply level.” Very few producers have been able to deliver what was agreed upon, she said.

Dried Bud

The situation is similar in Manitoba, where Winnipeg-based Delta 9 Cannabis Inc. only has dried bud on its store shelves as it has been unable to get any shipments of cannabis oils or gel caps, said spokesman Gary Symons. In the first seven days, Delta 9 saw close to 9,600 transactions totalling $736,124 in revenues. The company is now selling about $50,000 worth of product a day.

“Every province, not just Manitoba, is receiving less cannabis than originally requested,” Susan Harrison, spokeswoman for Manitoba Liquor & Lotteries, said in an email.

Aphria Inc. CEO Vic Neufeld predicted the supply shortages on the company’s earnings call five days before legalization. Citing supply-chain issues, labor shortages and delays in getting licences and excise stamps from the government, Neufeld said Aphria would be unable to meet demand in the first two to three months after legalization. The company was forced to destroy almost 14,000 plants worth $979,000 in the last quarter due to a lack of qualified greenhouse workers.

Extra Staff

There are currently 132 licensed producers in Canada and “many more are in the queue,” said Canadian Health Minister Ginette Petitpas Taylor. Health Canada has hired 300 additional staff to evaluate applications, she said. But the process, which includes background checks, is time-consuming and it’s important to not cut corners, she said.

“There’s not a mass shortage of cannabis around the country right now,” only certain strains that have sold out, Petitpas Taylor said. “We really have all hands on deck, we want to do what we can, but in no way am I going to compromise this new regime.”

The challenge for the government is balancing public safety with a desire to eradicate the illicit market, said Deepak Anand, vice president of business development and government relations at Cannabis Compliance Inc., a consulting firm for pot companies which is currently working on “hundreds” of licensing applications.

“Health Canada’s trying to balance quality and public safety with the need for getting more product on so that they can eliminate the black market,” Anand said. “Sometimes these goals conflict and compete with each other.”

The only near-term solution to the supply shortage, according to Durkacz at FSD Pharma, is to allow retailers to sell product sourced from the black market.

“You would instantaneously have a supply-demand balance and then you could try to convert people from the black market to the legalized market,” he said. “That’s probably the only way to solve this in the short term.”

Source: https://business.financialpost.com/cannabis/cannabis-business/marijuana-shortages-abound-in-canada-amid-licensing-rigmarole

#Marijuana Stocks: Three Key Catalysts for Further Growth $BOG.ca $NBUD.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 1:59 PM on Friday, October 26th, 2018

For most of 2018, marijuana stocks were the hottest opportunities around.

• Canopy Growth (CGC) ran from $20 to $57

• Tilray Inc. (TLRY) ran from $20 to $300

• OrganiGram Holdings (OGRMF) ran from $3 to $6.75

• Marijuana ETF, MJ ran from $26 to more than $44

All on anticipatory momentum as we neared Canadian approval this month. However, once the news was out, related stocks began to pull back on a “sell the news” reaction.

Once an expected catalyst is out, these are to be expected.

However, don’t count out marijuana stocks so fast, though. The catalysts ahead are monumental.

One – Americans Greatly Support its Legalization

A growing majority of Americans fully support its legalization, which has led to its decriminalization and the potential for significant cash inflows. In fact, 66% of Americans now support legalizing marijuana, another new high in Gallup’s trend. The latest figure marks the third consecutive year that support has increased.

Already, nine states and D.C. have legalized marijuana for recreational use.

As more states move to legalize its use, sales will skyrocket, in our opinion.

Two – Canada is Only the Start of the Boom

On October 17, 2018, marijuana became legal in Canada. But no one expected the demand to be as strong as it’s been. In fact, according to Fortune, the country can’t keep up with the pace of demand. Retail shops are nearly sold out.

It’s gotten so bad that stores have closed until the supply problem is fixed.

By 2021 analysts say Canada could have nearly four million recreational marijuana users, creating a monstrous $4.5 billion industry. The industry could balloon to $8.7 billion shortly thereafter, as marijuana retail sales just in Canada are likely to surpass beer, wine and spirit sales combined. That’s big money.

Three – Corporate America is on Board with Marijuana

As sales of beer fall in the United States, brewers have begun to bet that legalization of marijuana around the globe, especially the United States, will continue to build momentum and sales of cannabis products will take off.

Molson Coors for example listed legal cannabis among the biggest possible risks to its business in its annual shareholder report.

Even Bill Gates’ Microsoft jumped into the cannabis business on the software side, partnering with Kind Financial. The software will give governments and business owners a way to monitor the distribution of cannabis “from seed to sale” and ensure compliance.

Hewlett-Packard powers the Flowhub cannabis compliance solutions, too. Flowhub’s product not only provides business management and transactional processing tools for retail stores but also workflow focused on compliance, regulatory and reporting rules of marijuana dispensaries.

However, this is – we believe – is only the start. Pay close attention to this space.

Source: https://www.chasingmarkets.com/news/15bd33a6521b01/Marijuana_Stocks%3A_Three_Key_Catalysts_for_Further_Growth

Tetra Bio-Pharma $TBP.ca Appoints Richard Giguère Chief Executive Officer of Tetra Natural Health $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:30 AM on Wednesday, October 24th, 2018

Logo tetrabiopharma rgb web

  • Announced the appointment of Richard Giguère to the position of Chief Executive Officer of Tetra Natural Health Inc. a newly created, wholly owned subsidiary of Tetra Bio-Pharma Inc.
  • Mr. Giguère has more than 20 years’ experience in national sales and marketing in the pharmaceutical industry. During his career, he has held numerous business development, management and negotiation positions and launched several new products on the Canadian market

ORLEANS, Ontario, Oct. 24, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the appointment of Richard Giguère to the position of Chief Executive Officer of Tetra Natural Health Inc. a newly created, wholly owned subsidiary of Tetra Bio-Pharma Inc.

Mr. Giguère has more than 20 years’ experience in national sales and marketing in the pharmaceutical industry. During his career, he has held numerous business development, management and negotiation positions and launched several new products on the Canadian market. He has worked for several pharmaceutical companies in sectors such as generics, branded products and medical devices. He has also worked with OTC, natural products and original medications. Richard is recognized for his deep ethical sense, respect of others and talent for developing long-term business relationships. Over the past 10 years, he served as a member of the Board of Directors of the companies for which he worked.

“Richard has demonstrated his ability as a company builder which will prove crucial in his role as Chief Executive Officer of Tetra Natural Health,” stated Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc.  “He has begun preparing Tetra Natural Health as a wholly owned subsidiary of Tetra Bio-Pharma with the intentions of creating a market leader in the wellness sector of the cannabis market.”

“I am honored by this appointment as well by the confidence that Tetra Bio-Pharma has shown in me,” said Richard Giguère, CEO of Tetra Natural Health Inc. “As the CEO of Tetra Natural Health, I am excited and deeply committed to lead the operations of Tetra Natural Health with my colleagues through the next stages of development and success. Tetra has a sound business model, and there are several significant opportunities for Tetra Natural Health to grow and commercialize innovative natural health products. I am committed to exploiting the development of this huge potential market in the natural health sector.”

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

Canada to Open More Than 100 Pot Shops as It Becomes the Second Country to Legalize Marijuana $BOG.ca $NBUD.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 2:26 PM on Thursday, October 11th, 2018

  • On Oct. 17, Canada becomes the second and largest country with a legal national marijuana marketplace. Uruguay launched legal sales last year, after several years of planning.
  • It’s a profound social shift promised by Canadian Prime Minister Justin Trudeau and fueled by a desire to bring the black market into a regulated, taxed system after nearly a century of prohibition.

(DELTA, British Columbia) — Mat Beren and his friends used to drive by the vast greenhouses of southern British Columbia and joke about how much weed they could grow there.

Years later, it’s no joke. The tomato and pepper plants that once filled some of those greenhouses have been replaced with a new cash crop: marijuana. Beren and other formerly illicit growers are helping cultivate it. The buyers no longer are unlawful dealers or dubious medical dispensaries; it’s the Canadian government.

On Oct. 17, Canada becomes the second and largest country with a legal national marijuana marketplace. Uruguay launched legal sales last year, after several years of planning.

It’s a profound social shift promised by Canadian Prime Minister Justin Trudeau and fueled by a desire to bring the black market into a regulated, taxed system after nearly a century of prohibition.

It also stands in contrast to the United States, where the federal government outlaws marijuana while most states allow medical or recreational use for people 21 and older. Canada’s national approach has allowed for unfettered industry banking, inter-province shipments of cannabis, online ordering, postal delivery and billions of dollars in investment; national prohibition in the U.S. has stifled greater industry expansion there.

Hannah Hetzer, who tracks international marijuana policy for the New York-based Drug Policy Alliance, called Canada’s move “extremely significant,” given that about 25 countries have already legalized the medical use of marijuana or decriminalized possession of small amounts of pot. A few, including Mexico, have expressed an interest in regulating recreational use.

“It’s going to change the global debate on drug policy,” she said. “There’s no other country immediately considering legalizing the nonmedical use of cannabis, but I think Canada will provide almost the permission for other countries to move forward.”

At least 109 legal pot shops are expected to open across the nation of 37 million people next Wednesday, with many more to come, according to an Associated Press survey of the provinces. For now, they’ll offer dried flower, capsules, tinctures and seeds, with sales of marijuana-infused foods and concentrates expected to begin next year.

The provinces are tasked with overseeing marijuana distribution. For some, including British Columbia and Alberta, that means buying cannabis from licensed producers, storing it in warehouses and then shipping it to retail shops and online customers. Others, like Newfoundland, are having growers ship directly to stores or through the mail.

Federal taxes will total $1 per gram or 10 percent, whichever is more. The feds will keep one-fourth of that and return the rest to the provinces, which can add their own markups. Consumers also will pay local sales taxes.

Some provinces have chosen to operate their own stores, like state-run liquor stores in the U.S., while others have OK’d private outlets. Most are letting residents grow up to four plants at home.

Canada’s most populous province, Ontario, won’t have any stores open until next April, after the new conservative government scrapped a plan for state-owned stores in favor of privately run shops. Until then, the only legal option for Ontario residents will be mail delivery — a prospect that didn’t sit well with longtime pot fan Ryan Bose, 48, a Lyft driver.

“Potheads are notoriously very impatient. When they want their weed, they want their weed,” he said after buying a half-ounce at an illicit medical marijuana dispensary in Toronto. “Waiting one or two three days for it by mail, I’m not sure how many will want to do that.”

British Columbia, home of the “B.C. Bud” long cherished by American pot connoisseurs, has had a prevalent marijuana culture since the 1970s, after U.S. draft-dodgers from the Vietnam War settled on Vancouver Island and in the province’s southeastern mountains. But a change in government last year slowed cannabis distribution plans there, too, and it will have just one store ready next Wednesday: a state-run shop in Kamloops, a few hours’ drive northeast of Vancouver. By contrast, Alberta expects to open 17 next week and 250 within a year.

No immediate crackdown is expected for the dozens of illicit-but-tolerated medical marijuana dispensaries operating in British Columbia, though officials eventually plan to close any without a license. Many are expected to apply for private retail licenses, and some have sued, saying they have a right to remain open.

British Columbia’s ministry of public safety is forming a team of 44 inspectors to root out unlawful operations, seize product and issue fines. They’ll have responsibility for a province of 4.7 million people and an area twice as large as California, where the black market still dwarfs the legal market that arrived in January.

Chris Clay, a longtime Canadian medical marijuana activist, runs Warmland Centre dispensary in an old shopping mall in Mill Bay, on Vancouver Island. He is closing the store Monday until he gets a license; he feared continuing to operate post-legalization would jeopardize his chances. Some of his eight staff members will likely have to file for unemployment benefits in the meantime.

“That will be frustrating, but overall I’m thrilled,” Clay said. “I’ve been waiting decades for this.”

The federal government has licensed 120 growers, some of them enormous. Canopy Growth, which recently received an investment of $4 billion from Constellation Brands, whose holdings include Corona beer, Robert Mondavi wines and Black Velvet whiskey, is approved for 5.6 million square feet (520,000 square meters) of production space across Canada. Its two biggest greenhouses are near the U.S. border in British Columbia.

Beren, a 23-year cannabis grower, is a Canopy consultant.

“We used to joke around all the time when we’d go to Vancouver and drive by the big greenhouses on the highway,” he said. “Like, ‘Oh man, someday. It’d be so awesome if we could grow cannabis in one of these greenhouses.’ We drive by now, and we’re like, ‘Oh, we’re here.’”

Next to Canopy’s greenhouse in Delta is another huge facility, Pure Sunfarms, a joint venture between a longtime tomato grower, Village Farms International, and a licensed medical marijuana producer, Emerald Health Therapeutics. Workers pulled out the remaining tomato plants last winter and got to work renovating the greenhouse as a marijuana farm, installing equipment that includes lights and accordion-shaped charcoal vents to control the plant’s odor. By 2020, the venture expects to move more than 165,000 pounds (75,000 kg) of bud per year.

Some longtime illegal growers who operate on a much smaller scale worry they won’t get licensed or will get steamrolled by much larger producers. Provinces can issue “micro-producer” licenses. But in British Columbia, where small-time pot growers helped sustain rural economies as the mining and forestry industries cratered, the application period hasn’t opened yet.

Sarah Campbell of the Craft Cannabis Association of BC said many small operators envision a day when they can host visitors who can tour their operations and sample the product, as wineries do.

Officials say they intend to accommodate craft growers but first need to ensure there is enough cannabis to meet demand when legalization arrives. Hiccups are inevitable, they say, and tweaks will be needed.

“Leaving it to each province to decide what’s best for their communities and their citizens is something that’s good,” said Gene Makowsky, the Saskatchewan minister who oversees the province’s Liquor and Gaming Authority. “We’ll be able to see if each law is successful or where we can do better in certain areas.”

British Columbia safety minister Mike Farnworth said he learned two primary lessons by visiting Oregon and Washington, U.S. states with recreational marijuana. One was not to look at the industry as an immediate cash cow, as it will take time to displace the black market. The other was to start with relatively strict regulations and then loosen them as needed, because it’s much harder to tighten them after the fact.

Legalization will be a process more than a date, Farnworth said.

“Oct. 17th is actually not going to look much different than it does today,” he said.

Source: http://time.com/5421443/canada-legal-marijuana-sales/

CLIENT FEATURE: Bougainville Ventures $BOG.ca a Turnkey Greenhouse Growing Infrastructure Provider $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 11:08 AM on Wednesday, October 10th, 2018

WHY BOUGAINVILLE?

  • Converting irrigated farmland to greenhouse-equipped farmland
  • Bougainville does not “touch the plant” by only providing agricultural infrastructure as a landlord for licensed marijuana growers
  • First 10,000 square feet (of 30,000 sqf) greenhouse space has been completed
  • Ready for occupancy
  • Room for expansion
  • Facility projected to produce in excess of 12,000 lbs. of high quality cannabis per annum upon completion of all greenhouses
  • JV Agreement with Marijuana Company of America (MCOA:OTC)
  • MCOA investment of $1M

Early estimates show a greenhouse can produce twice the amount of product and at least less than 50% of the cost compared to warehouse production.

FULL DISCLOSURE: Bougainville Ventures is an advertising client of AGORA Internet Relations Corp.

CLIENT FEATURE: Bougainville Ventures $BOG.ca a Turnkey Greenhouse Growing Infrastructure Provider $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 11:08 AM on Friday, September 28th, 2018

681747 5720 copy 2

WHY BOUGAINVILLE?

  • Converting irrigated farmland to greenhouse-equipped farmland
  • Bougainville does not “touch the plant” by only providing agricultural infrastructure as a landlord for licensed marijuana growers
  • First 10,000 square feet (of 30,000 sqf) greenhouse space has been completed
  • Ready for occupancy
  • Facility projected to produce in excess of 12,000 lbs. of high quality cannabis per annum upon completion of all greenhouses
  • JV Agreement with Marijuana Company of America (MCOA:OTC)
  • MCOA investment of $1M

Early estimates show a greenhouse can produce twice the amount of product and at least less than 50% of the cost compared to warehouse production.

FULL DISCLOSURE: Bougainville Ventures is an advertising client of AGORA Internet Relations Corp.

#Cannabis-laced drinks could be a US$600m market in US by 2022 $NBUD.ca $TAP $WEED.ca $KO

Posted by AGORACOM-JC at 10:18 AM on Friday, September 28th, 2018
  • Beverages with CBD (cannabidiol) or THC (tetrahydrocannabinol) ingredients could grow to capture about 20 per cent of the US market for edible pot products by 2022, up from 6 per cent of edibles sold now
  • Canaccord sees the demand for beverages featuring CBD, the non-psychoactive compound in marijuana, reaching US$260 million by 2022, up from the “negligible revenue” the limited number of drinks contributes now, while THC-based drinks could reach US$340 million, up from US$106 million expected this year

Sep 27, 2018 (Euclid Infotech Ltd via COMTEX) — Drinks infused with marijuana-derived compounds could swell to become a US$600 million market in the US within the next four years, outpacing the growth of other categories of retail cannabis products, according to analysts at Canaccord Genuity.

Beverages with CBD (cannabidiol) or THC (tetrahydrocannabinol) ingredients could grow to capture about 20 per cent of the US market for edible pot products by 2022, up from 6 per cent of edibles sold now, Canaccord’s Bobby Burleson wrote in a note. It’s an opportunity mainstream beer and soda makers are eager to take part in – Corona-parent Constellation Brands Inc became the largest stakeholder in Canadian pot cultivator Canopy Growth Corp earlier this year, while Molson Coors Canada formed a joint venture with Hexo Corp. Also, Coca-Cola Co said it’s exploring the idea.

“Interest has spiked from the beer industry on mounting evidence of a substitution relationship between cannabis and alcohol, while large soda companies increasingly view CBD as a natural fit within their strategically important wellness offerings,” Mr Burleson wrote.

Canaccord sees the demand for beverages featuring CBD, the non-psychoactive compound in marijuana, reaching US$260 million by 2022, up from the “negligible revenue” the limited number of drinks contributes now, while THC-based drinks could reach US$340 million, up from US$106 million expected this year.

Source: https://www.marketwatch.com/press-release/united-states-cannabis-laced-drinks-could-be-a-us600m-market-in-us-by-2022-2018-09-27

Bougainville Venture’s $BOG.ca Oroville, WA Cultivation Facility Ready for Occupancy $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 1:02 PM on Thursday, September 27th, 2018

681747 5720 copy 2

  • Cultivation facility in Oroville, WA will be occupied by a Tier-3, I-502 tenant within the next weeks
  • The tenant is in the final process of obtaining approval of plans and issuance of permits from Okanogan County and Washington State Liquor Cannabis Board (WSLCB)

Vancouver, BC / September 27, 2018 – BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company”) (CSE: BOG), providing cannabis infrastructure and seed-to-sale services to I-502 tenant-growers, is pleased to announce that its cultivation facility in Oroville, WA will be occupied by a Tier-3, I-502 tenant within the next weeks. The tenant is in the final process of obtaining approval of plans and issuance of permits from Okanogan County and Washington State Liquor Cannabis Board (WSLCB).

Our Cultivation Facility

Our initial facility is situated on prime farmland in Oroville, WA with easy access to transportation, industrial infrastructure, power, water, gas, and courier services in the northern region of the Okanagan Valley.

The cultivation facility consists of 6 greenhouses providing a total of 30,000 sq. ft. of cultivation area. Three of the greenhouses are complete. Final construction of all 6 greenhouses is expected to be completed in February, 2019.

The Oroville facility is projected to produce in excess of 12,000 lbs. of high quality cannabis per annum upon completion of all the greenhouses.

CEO, Andy Jagpal Comments:

“Our Oroville facilities are now ready for our first tenant to take occupancy. We are also in the final stages of signing other I-502 tenants for this facility. In addition, we are in the process of acquiring new cultivation facilities in other cannabis-approved jurisdictions.”

About Bougainville Ventures, Inc.
Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost. Bougainville has 30,000 sq ft in near production in Oroville, WA.

For more information please visit: http://bougainvilleinc.com/

 

On behalf of the Board of Directors

BOUGAINVILLE VENTURES INC.

_____________________

Andy Jagpal, CEO and Director

For further information, please contact Andy Jagpal at [email protected] or 1-844-734-8420 ____________

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws, including statements regarding the Oroville, WA cultivation facility: statements pertaining to the ability of Bougainville Ventures Inc. (“BOG”); the anticipated economic potential of the property; the availability of capital and finance for BOG to execute its strategy going forward. Forward-looking statements are based on estimates and assumptions made by BOG in light of its experience and perception of current and expected future developments, as well as other factors that BOG believes are appropriate in the circumstances. Many factors could cause BOG’s results, performance or achievements to differ materially from those expressed or implied by the forward looking statements, including: discrepancies between actual and estimated results from exploration and development and operating risks, dependence on early exploration stage concessions; uninsurable risks; competition; regulatory restrictions, including environmental regulatory restrictions and liability; currency fluctuations; defective title to mineral claims or property and dependence on key employees. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Tetra Bio-Pharma $TBP.ca Takes One Step Closer to the Commercialization of Cannabis Oil-Based Retail Products $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:00 AM on Monday, September 24th, 2018

Logo tetrabiopharma rgb web

  • Made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market
  • Tetra and its clinical research partner, Santé Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised

ORLEANS, Ontario, Sept. 24, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), has made significant progress in its clinical trial for PPP005 the cannabis oil-based capsules destined for the natural health products market.

Tetra and its clinical research partner, Santé Cannabis, announced that the clinical trial in non-cancer chronic pain patients will be completed later this autumn as promised.  This was the first clinical trial of its kind in evaluating the safety and efficacy of different doses and ratios of cannabis oils versus placebo.  The study included a dose titration phase (gradually bringing patients to the required dose) allowing us to better understand the side effect profile of the oils as well as the development of tolerance to these effects.  Thus far, no other company in the medical cannabis space has undertaken such an exhaustive study to understand the therapeutic benefits and side effects of a cannabis oil-based capsule.

Dr. Chamberland, interim CEO and CSO added, “We continue to deliver on our business model that provides for evidence-based research to support the usage of cannabis-derived products and provide the medical community with the data they have been demanding from this sector. The trial has already provided unique valuable clinical data on both safe and efficacious dose levels of CBD and THC-CBD oils.  This data will allow Tetra to advance to the next phase of product development wherein the company is developing products for its commercial partner Genacol Corporation Canada, as well as food supplements for the retail market and finally, our capsules that we intend to use in the treatment of chronic and cancer related pain.  Tetra has already established itself as a trailblazer in the natural health product segment with the announcement of our intention to launch a Hemp Energy Drink and we intend to build on that momentum.”

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of PPP005, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]